SEARCH

Current Edition

Breyanzi

Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers’ acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol …

Continue Reading →